VXRT - Enrollment underway in Vaxart's early-stage norovirus trial in elderly population

Vaxart (VXRT) has enrolled the first subject in a Phase 1b trial, VXA-NVV-104, evaluating safety and immunogenicity of oral norovirus vaccine in elderly subjects aged 55 – 80 years. The study drug will be an oral tablet administered on Days 1 and 29. “The norovirus program is part of our broader strategy to develop prophylactic vaccines that target a range of pathogens,” said Andrei Floroiu, CEO. Norovirus vaccine candidate is being evaluated in a comprehensive clinical program that is currently scheduled to include at least four clinical trials in 2021. Norovirus is an enteric pathogen that infects epithelial cells of the small intestine. Vaxart also expects to launch a Phase 2 norovirus human challenge study later this year.VXRT shares down 2% premarket trading at $6.80.Previously (May 4): Vaxart starts enrollment in early-stage norovirus boosting regimen study

For further details see:

Enrollment underway in Vaxart's early-stage norovirus trial in elderly population